Literature DB >> 11059474

A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.

P J Neumann1, E A Sandberg, S S Araki, K M Kuntz, D Feeny, M C Weinstein.   

Abstract

PURPOSE: The Health Utilities Index (HUI) is a generic, multiattribute, preference-based health-status classification system. The HUI Mark 3 (HUI3) differs from the earlier HUI2 by modifying attributes and allowing more flexibility for capturing high levels of impairment. The authors compared HUI2 and HUI3 scores of patients with Alzheimer's disease (AD) and caregivers, and contrasted results of a cost-effectiveness analysis of new drugs for AD using the two systems.
METHODS: In a cross-sectional study of 679 AD patient/caregiver pairs, stratified by patient's disease stage (questionable/mild/moderate/severe/profound/terminal) and setting (community/assisted living/nursing home), caregivers completed the combined HUI2/HUI3 questionnaire as proxy respondents for patients and for themselves.
RESULTS: Mean (SD) global utility scores for patients were lower on the HUI3 (0.22[0.26]) than on the HUI2 (0.53 [0.21]). Patient HUI3 utility scores ranged from 0.47(0.24) for questionable AD to -0.23 (0.08) for terminal AD, compared with a range of 0.73 (0.15) to 0.14 (0.07) for the HUI2. Among the 203 patients in the severe, profound, and terminal stages, 96 (48%) had negative global HUI3 utility scores, while none had a negative HUI2 score. The utility scores for caregivers were similar on the HUI3 (0.87 [0.14]) and HUI2 (0.87 [0.11]). Cost-effectiveness analysis of a new medication to treat AD showed somewhat more favorable results using the HUI3.
CONCLUSIONS: The HUI2 and HUI3 discriminate well across AD stages. Compared with the HUI2, the HUI3 yields lower global utility scores for patients with AD, and more scores for states judged worse than dead. The HUI3 may yield substantially different results from the HUI2, particularly for persons who have serious cognitive impairments such as AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059474     DOI: 10.1177/0272989X0002000405

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  32 in total

1.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Correlates of health-related quality of life in type 2 diabetes.

Authors:  D J Wexler; R W Grant; E Wittenberg; J L Bosch; E Cagliero; L Delahanty; M A Blais; J B Meigs
Journal:  Diabetologia       Date:  2006-04-29       Impact factor: 10.122

3.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  A review of quality of life instruments used in dementia.

Authors:  Teake P Ettema; Rose-Marie Dröes; Jacomine de Lange; Gideon J Mellenbergh; Miel W Ribbe
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

5.  Utility-based Quality of Life measures in Alzheimer's disease.

Authors:  Gary Naglie; George Tomlinson; Catherine Tansey; Jane Irvine; Paul Ritvo; Sandra E Black; Morris Freedman; Michel Silberfeld; Murray Krahn
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

6.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis.

Authors:  Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation.

Authors:  Christine M McDonough; Tor D Tosteson; Anna N A Tosteson; Alan M Jette; Margaret R Grove; James N Weinstein
Journal:  Med Decis Making       Date:  2010-11-22       Impact factor: 2.583

9.  Longitudinal construct validity of the Health Utilities Indices Mark 2 and Mark 3 in hip fracture.

Authors:  C Allyson Jones; Sheri L Pohar; David H Feeny; Ken Eng
Journal:  Qual Life Res       Date:  2013-10-01       Impact factor: 4.147

Review 10.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.